Rol de infliximab en enfermedad inflamatoria intestinal: Experiencia local

Background: Biological therapy has an important role in the treatment of Inflammatory Bowel Disease (IBD). However, the use of these drugs is resisted due to fears about their side effects. Aim: To report the experience with the use of Infliximab in patients with IBD. Material and Methods: Descripti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Simian,Daniela, Quijada,María Isabel, Lubascher,Jaime, Acuña,Raúl, Quera,Rodrigo
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2013
Materias:	Antibodies, monoclonal Colitis, ulcerative Crohn disease Infliximab
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872013000900008
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872013000900008
record_format	dspace
spelling	oai:scielo:S0034-988720130009000082014-09-02Rol de infliximab en enfermedad inflamatoria intestinal: Experiencia localSimian,DanielaQuijada,María IsabelLubascher,JaimeAcuña,RaúlQuera,Rodrigo Antibodies, monoclonal Colitis, ulcerative Crohn disease Infliximab Background: Biological therapy has an important role in the treatment of Inflammatory Bowel Disease (IBD). However, the use of these drugs is resisted due to fears about their side effects. Aim: To report the experience with the use of Infliximab in patients with IBD. Material and Methods: Descriptive study of a historical cohort of patients with IBD treated between 2007 and 2012 with Infliximab. A favorable clinical response was considered when general, intestinal and extra-intestinal symptoms subsided after the second or third dose of the drug. Endoscopic or imaging response was evaluated between three and six months of treatment. Results: Twenty five patients aged 18 to 61 years (12 women) were included. Sixteen had Cohns Disease and 9 had Ulcerative Colitis. Treatment was indicated due to refractory disease in 13 patients, perianal involvement in nine, stenosis in two and pyoderma gangrenosum in one. Ten patients initiated Infliximab within less than two years of diagnosis. Twenty-two patients received combined treatment with immunosuppressive medications and the other three patients were treated exclusively with Infliximab. A favorable clinical response was observed in 88% after the second dose and 64% had endoscopic or imaging remission after 3-6 months. Twelve patients discontinued Infliximab, due to bad response to treatment in three patients, economic cost in three patients, and patient/doctor decision in six. Only three patients had side effects (herpes zoster and sinusitis). None of these motivated the discontinuation of treatment. Conclusions: In this cohort of patients with IBD, the use of Infliximab was associated with endoscopic or imaging remission in 64% of cases after 3-6 months of treatment with no major side effects.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.141 n.9 20132013-09-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872013000900008es10.4067/S0034-98872013000900008
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Antibodies, monoclonal Colitis, ulcerative Crohn disease Infliximab
spellingShingle	Antibodies, monoclonal Colitis, ulcerative Crohn disease Infliximab Simian,Daniela Quijada,María Isabel Lubascher,Jaime Acuña,Raúl Quera,Rodrigo Rol de infliximab en enfermedad inflamatoria intestinal: Experiencia local
description	Background: Biological therapy has an important role in the treatment of Inflammatory Bowel Disease (IBD). However, the use of these drugs is resisted due to fears about their side effects. Aim: To report the experience with the use of Infliximab in patients with IBD. Material and Methods: Descriptive study of a historical cohort of patients with IBD treated between 2007 and 2012 with Infliximab. A favorable clinical response was considered when general, intestinal and extra-intestinal symptoms subsided after the second or third dose of the drug. Endoscopic or imaging response was evaluated between three and six months of treatment. Results: Twenty five patients aged 18 to 61 years (12 women) were included. Sixteen had Cohns Disease and 9 had Ulcerative Colitis. Treatment was indicated due to refractory disease in 13 patients, perianal involvement in nine, stenosis in two and pyoderma gangrenosum in one. Ten patients initiated Infliximab within less than two years of diagnosis. Twenty-two patients received combined treatment with immunosuppressive medications and the other three patients were treated exclusively with Infliximab. A favorable clinical response was observed in 88% after the second dose and 64% had endoscopic or imaging remission after 3-6 months. Twelve patients discontinued Infliximab, due to bad response to treatment in three patients, economic cost in three patients, and patient/doctor decision in six. Only three patients had side effects (herpes zoster and sinusitis). None of these motivated the discontinuation of treatment. Conclusions: In this cohort of patients with IBD, the use of Infliximab was associated with endoscopic or imaging remission in 64% of cases after 3-6 months of treatment with no major side effects.
author	Simian,Daniela Quijada,María Isabel Lubascher,Jaime Acuña,Raúl Quera,Rodrigo
author_facet	Simian,Daniela Quijada,María Isabel Lubascher,Jaime Acuña,Raúl Quera,Rodrigo
author_sort	Simian,Daniela
title	Rol de infliximab en enfermedad inflamatoria intestinal: Experiencia local
title_short	Rol de infliximab en enfermedad inflamatoria intestinal: Experiencia local
title_full	Rol de infliximab en enfermedad inflamatoria intestinal: Experiencia local
title_fullStr	Rol de infliximab en enfermedad inflamatoria intestinal: Experiencia local
title_full_unstemmed	Rol de infliximab en enfermedad inflamatoria intestinal: Experiencia local
title_sort	rol de infliximab en enfermedad inflamatoria intestinal: experiencia local
publisher	Sociedad Médica de Santiago
publishDate	2013
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872013000900008
work_keys_str_mv	AT simiandaniela roldeinfliximabenenfermedadinflamatoriaintestinalexperiencialocal AT quijadamariaisabel roldeinfliximabenenfermedadinflamatoriaintestinalexperiencialocal AT lubascherjaime roldeinfliximabenenfermedadinflamatoriaintestinalexperiencialocal AT acunaraul roldeinfliximabenenfermedadinflamatoriaintestinalexperiencialocal AT querarodrigo roldeinfliximabenenfermedadinflamatoriaintestinalexperiencialocal
_version_	1718436711449493504

Rol de infliximab en enfermedad inflamatoria intestinal: Experiencia local

Ejemplares similares